{"prompt":"Title: 10 mg IR in Study 326 Description: Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.\n\n$$$\n\n","completion":" Donepezil SR | Donepezil ###"}
{"prompt":"Title: 23 mg SR in Study 326 Description: Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.\n\n$$$\n\n","completion":" Donepezil SR | Donepezil ###"}
{"prompt":"Title: A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm Description: Rituximab: 375 mg\/m2 intravenous (IV), day 1 for patients (pts) with cluster of differentiation 20-positive disease. Allogenic stem cell transplant (txplt). Fludarabine:30 mg\/m2 per day IV over 30 min. daily. On days -6, -5, -4, and -3. Cyclophosphamide:1200 mg\/m2 per day IV over 2 hrs on Days 6, -5, -4, -3. Mesna:1200 mg\/m2 per day IV, Daily on days 6, -5,-4, and -3.Tacrolimus: day -3 before txplt, 0.02 mg\/kg\/day CIV, then switch to an equivalent oral dose (when pts taking po) titrated for a goal level of 5-10 ng\/ml; Sirolimus: loading dose of 12 mg p.o. on day -3 pre-txplt, 4 mg day -2 pre-txplt and titrated for levels 3-12 ng\/ml; Methotrexate 5 mg\/m2 IV on days +1, +3, +6, and +11 post txplt). Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-txplt as tolerated. Fludarabine:25 mg\/m2 per day IV over 30 minutes, Daily on days 1-5.Cytarabine: 2,000 mg\/m2 IV over 4 hrs, on Days 1, 2, 3, 4, 5. Filgrastim: 5 mcg\/kg per day SC beginning 24 hrs before chemo.\n\n$$$\n\n","completion":" Methotrexate | Mesna | Rituximab | Filgrastim | Cytarabine | Tacrolimus | Fludarabine | Sirolimus | Cyclophosphamide ###"}
{"prompt":"Title: A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm Description: Rituximab:375 mg\/m2 IV, day 1 for patients with CD20-positive disease. Allogenic stem cell transplant (ASCT):Conditioning Chemotherapy:Fludarabine:30 mg\/m2 per day IV infusion over 30 minutes, daily On days -6, -5, -4, and -3. Cyclophosphamide:1200 mg\/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3.Mesna: 1200 mg\/m2 per day IV infusion, Daily on days 6, -5,-4, and -3.Tacrolimus: 0.02 mg\/kg, start day 3. Continue IV or PO. Taper will begin at day +63 if no acute GVHD then at day +119 and discontinue at day +180 as tolerated. Methotrexate: 5mg\/m2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 63, followed by a taper if GVHD does not develop. Sirolimus: 12 mg PO on days -3 to 63, followed by a taper if GVHD does not develop.FLAG: Fludarabine:25 mg\/m2 per day IV over 30 minutes, Daily on days 1-5. Cytarabine: 2,000 mg\/m2 IV over 4 hours, on Days 1, 2, 3, 4, 5. Filgrastim: 5 mcg\/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy\n\n$$$\n\n","completion":" Rituximab | Filgrastim | Cytarabine | Fludarabine | Tacrolimus | Sirolimus | Cyclophosphamide | Methotrexate | Mesna ###"}
{"prompt":"Title: A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm Description: TMS Arm Rituximab: 375 mg\/m2 IV, day 1 for patients with cluster of differentiation 20 (CD20)-positive disease Allogenic stem cell transplant (ASCT):Allogenic stem cell transplant Conditioning Chemotherapy:Fludarabine:30 mg\/m2 per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3 Cyclophosphamide:1200 mg\/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna:1200 mg\/m2 per day IV infusion, Daily on days 6, -5,-4, and -3 TMS: Tacrolimus: 0.02 mg\/kg, start day 3. Continue IV or PO. Taper will begin at day +63 if no acute GVHD then at day +119 and discontinue at day +180 as tolerated Methotrexate: 5 mg\/m2 IV over 15 minutes on days 1, 3, 6, and 11 Sirolimus: 12 mg PO on days -3 to 63, followed by a taper if GVHD does not develop.\n\nFLAG: Fludarabine:25 mg\/m2 per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg\/m2 IV over 4 hours, on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg\/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy\n\n$$$\n\n","completion":" Filgrastim | Cytarabine | Tacrolimus | Cyclophosphamide | Fludarabine | Sirolimus | Methotrexate | Rituximab | Mesna ###"}
{"prompt":"Title: ACC-001 10 Micrograms + QS-21 Description: A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12\n\n$$$\n\n","completion":" Acc-001 | Qs-21 ###"}
{"prompt":"Title: ACC-001 3 Micrograms + QS-21 Description: A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12\n\n$$$\n\n","completion":" Acc-001 | Qs-21 ###"}
{"prompt":"Title: ACC-001 3 Micrograms + QS-21 Description: A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 3, 6, 9 and 12\n\n$$$\n\n","completion":" Acc-001 | Qs-21 ###"}
{"prompt":"Title: ACC-001 30 Micrograms + QS-21 Description: A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12\n\n$$$\n\n","completion":" Acc-001 | Qs-21 ###"}
{"prompt":"Title: Active Group: Ketamine+MET Description: 50-minute intravenous infusion of ketamine (0.71 mg\/kg) administered during the second week of a five week regimen of motivational enhancement therapy.\n\n$$$\n\n","completion":" Met | Ketamine ###"}
{"prompt":"Title: All Phase I Particiapnts Description: All Phase I participants received plerixafor by injection and bortezomib intravenously according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.\n\n$$$\n\n","completion":" Plerixafor | Bortezomib ###"}
{"prompt":"Title: Arm 1: (Docetaxel, Carboplatin, Pegylated G-CSF) Description: Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles\nPegylated G-CSF on day 2 every 21 days for maximum of 6 cycles\n\n$$$\n\n","completion":" Pegylated G-CSF | Docetaxel | Carboplatin ###"}
{"prompt":"Title: Arm I: Docetaxel Description: Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who progress also receive oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of a second disease progression or unacceptable toxicity.\n\ndocetaxel: Given IV\n\nvandetanib: Given orally\n\n$$$\n\n","completion":" Docetaxel | Vandetanib ###"}
{"prompt":"Title: Arm II: Docetaxel + Vandetanib Description: Patients receive docetaxel IV over 1 hour on day 1 and oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\ndocetaxel: Given IV\n\nvandetanib: Given orally\n\n$$$\n\n","completion":" Docetaxel | Vandetanib ###"}
{"prompt":"Title: B - Cyclosporine (AC) Arm Description: Rituximab375 mg\/m2 IV, day 1 for pts with CD20-positive disease. Cyclosporine IV over 2 hrs or orally every 12 hrs on days -1-100, followed by a taper if GVHD does not develop. Allogenic stem cell transplant. Conditioning Chemotherapy Fludarabine:30 mg\/m2 per day IV infusion over 30 min., daily on days -6, -5, -4, and -3. Cyclophosphamide1200 mg\/m2 per day IV infusion over 2 hrs on Days 6, -5, -4, -3. Mesna1200 mg\/m2 per day IV infusion, Daily on days 6, -5,-4, and -3. FLAG: Fludarabine25 mg\/m2 per day IV over 30 min., Daily on days 1-5. Cytarabine 2,000 mg\/m2 IV over 4 hrs, on Days 1, 2, 3, 4, 5. Filgrastim 5 mcg\/kg per day SC beginning 24 hrs PRIOR to start of chemotherapy. EPOCH-F: Fludarabine25 mg\/m2 per day IV infusion over 30 min., daily on days 1-4. Etoposide 50 mg\/m2 per day continuous IV infusion over 24 hrs on days 1-4. Doxorubicin10 mg\/m2\/d. Grp 2 Alemtuzumab for 4 days starting 8 days before SCT + cyclosporine starting 1 day before SCT and continuing for 6 months.\n\n$$$\n\n","completion":" Doxorubicin | Rituximab | Cyclophosphamide | Fludarabine | Cyclosporine | Etoposide | Cytarabine | Alemtuzumab | Mesna | Filgrastim ###"}
{"prompt":"Title: BRCA-positive Ovarian Cancer: ABT-888 & Cyclophosphamide Description: Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.\n\n$$$\n\n","completion":" Cyclophosphamide | Abt-888 ###"}
{"prompt":"Title: BRCA-positive Ovarian Cancer: Crossover Description: Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.\n\n$$$\n\n","completion":" Abt-888 | Cyclophosphamide ###"}
{"prompt":"Title: Bortezomib After HD melphalanAll Description: patients received melphalan (100 mg\/m^2\/day \u00d7 2; days\n\n-3 and -2), for a total dose of 200 mg\/m^2. Patients were randomized to receive bortezomib 24 hours after administration of high-dose melphalan in escalating dose cohorts of 1.0, 1.3, and 1.6 mg\/m^2\n\n$$$\n\n","completion":" Melphalan | Bortezomib | Melphalanall ###"}
{"prompt":"Title: Bortezomib Before HD Melphalan Description: All patients received melphalan (100 mg\/m^2\/day \u00d7 2; days\n\n-3 and -2), for a total dose of 200 mg\/m^2. Patients were randomized to receive bortezomib 24 hours before administration of high-dose melphalan in escalating dose cohorts of 1.0, 1.3, and 1.6 mg\/m^2\n\n$$$\n\n","completion":" Melphalan | Bortezomib ###"}
{"prompt":"Title: Bortezomib and Dexamethasone Description: Participants received bortezomib (Velcade) 1.3 mg\/m^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg\/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).\n\n$$$\n\n","completion":" Bortezomib | Dexamethasone ###"}
{"prompt":"Title: Bortezomib, Melphalan and Prednisone Description: Participants received bortezomib 1.3 mg\/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg\/m^2 orally on Days 1-4 every other cycle and prednisone 60 mg\/m^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg\/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).\n\n$$$\n\n","completion":" Melphalan | Bortezomib | Prednisone ###"}
{"prompt":"Title: Bortezomib, Thalidomide, and Dexamethasone Description: Participants received bortezomib 1.3 mg\/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg\/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).\n\n$$$\n\n","completion":" Bortezomib | Dexamethasone | Thalidomide ###"}
{"prompt":"Title: Carboplatin\/Paclitaxel\/Bevacizumab Then Bevacizumab Description: Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg\/m2 and bevacizumab IV 15 mg\/kg on day 1 (+\/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.\n\nPatients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.\n\nConsolidation (A): Patients received bevacizumab IV 15 mg\/kg on day 1 (+\/- 3d) of a 21 day cycle for 1 year.\n\n$$$\n\n","completion":" Paclitaxel | Carboplatin | Bevacizumab ###"}
{"prompt":"Title: Carboplatin\/Paclitaxel\/Bevacizumab Then Bevacizumab\/Erlotinib Description: Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg\/m2 and bevacizumab IV 15 mg\/kg on day 1 (+\/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.\n\nPatients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.\n\nConsolidation (AE): Patients received bevacizumab IV 15 mg\/kg on day 1 (+\/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year.\n\n$$$\n\n","completion":" Carboplatin | Erlotinib | Paclitaxel | Bevacizumab ###"}
{"prompt":"Title: Carboxymethylcellulose 0.5%, Glycerin 0.9% Description: carboxymethylcellulose 0.5%, glycerin 0.9%\n\n$$$\n\n","completion":" Glycerin | Carboxymethylcellulose ###"}
{"prompt":"Title: Chemotherapy With Stem Cell Support Description: This is a phase I\/II trial of sequential accelerated chemotherapy cycles with paclitaxel\/ifosfamide and paclitaxel\/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38.\n\nfilgrastim\n\ncarboplatin\n\nifosfamide\n\npaclitaxel\n\nautologous hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\n$$$\n\n","completion":" Paclitaxel | Ifosfamide | Filgrastim | Carboplatin ###"}
{"prompt":"Title: Ciclesonide + Placebo Description: Ciclesonide: Low dose inhaled corticosteroid (80 mcg\/puff two puffs twice daily)\n\n$$$\n\n","completion":" Ciclesonide | Placebo ###"}
{"prompt":"Title: Ciclesonide + Vitamin D Description: Vitamin D3: vitamin D (100,000 IU loading dose followed by 4,000 IU\/day)\n\nCiclesonide: Low dose inhaled corticosteroid (80 mcg\/puff two puffs twice daily)\n\n$$$\n\n","completion":" Vitamin D | Ciclesonide ###"}
{"prompt":"Title: Cohort 1 (Erlotinib Plus Romidepsin (8 mg\/m^2)) Description: Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg\/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.\n\n$$$\n\n","completion":" Romidepsin | Erlotinib ###"}
{"prompt":"Title: Cohort 2 (Erlotinib Plus Romidepsin (10 mg\/m^2)) Description: Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg\/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.\n\n$$$\n\n","completion":" Romidepsin | Erlotinib ###"}
{"prompt":"Title: Cohort 3 (Erlotinib Plus Romidepsin (10 mg\/m^2)) + Antiemetic Prophylaxis Description: Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg\/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.\n\n$$$\n\n","completion":" Romidepsin | Erlotinib ###"}
{"prompt":"Title: Cohort 4 (Erlotinib Plus Romidepsin (8 mg\/m^2)) + Antiemetic Prophylaxis Description: Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg\/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.\n\n$$$\n\n","completion":" Erlotinib | Romidepsin ###"}
{"prompt":"Title: Control Group: Midazolam+MET Description: 50-minute intravenous infusion of the active control midazolam (0.025 mg\/kg), administered during the second week of a five week regimen of motivational enhancement therapy.\n\n$$$\n\n","completion":" Midazolam | Met ###"}
{"prompt":"Title: Delayed Switch Description: Patients randomized to the delayed switch group were switched to 5 cm^2 rivastigmine patch formulation on Day 8, following a 7-day withdrawal period from donepezil. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.\n\n$$$\n\n","completion":" Rivastigmine | Donepezil ###"}
{"prompt":"Title: Dexedrine+tDCS+Speech Therapy Description: 10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day\n\nDexedrine: 10 mg immediate release of Dexedrine\n\nActive tDCS: 1.5 mA tDCS anodal tDCS\n\nSpeech Therapy: 60 min of speech therapy\n\n$$$\n\n","completion":" Tdcs | Dexedrine ###"}
{"prompt":"Title: Dexedrine+tDCS+Speech Therapy Description: The subjects received 10 mg D-AMP 30 minutes before the 60 minutes of SLT; first 20 min is simultaneous tDCS stimulation in this experiment\/arm.\n\n$$$\n\n","completion":" Dexedrine | Tdcs ###"}
{"prompt":"Title: Doubling Statin Dose Description: simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.\n\n$$$\n\n","completion":" Simvastatin | Atorvastatin ###"}
{"prompt":"Title: Duloxetine Description: Duloxetine: 40 mg capsule, Once daily\/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg\/d or reduced to 20 mg\/d based on subject response and tolerability.\n\nStandardized behavioral therapy: Standardized behavioral therapy 1 time per week for 12 week duration.\n\n$$$\n\n","completion":" Duloxetine | Placebo ###"}
{"prompt":"Title: Dupilumab 300 mg q2w Description: 2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20.\n\n$$$\n\n","completion":" Prednisone | Dupilumab | Prednisolone ###"}
{"prompt":"Title: Elotuzumab 10 mg\/kg Description: Elotuzumab 10 mg\/kg was intravenously (IV) given weekly (Days 1, 8, 15 and 22 of 4-week cycle) for the first 2 cycles and bi-weekly (every 2 weeks) (Day 1 and Day 15) thereafter until disease progression or unacceptable toxicity. Elotuzumab was first given at 10 mg\/kg. If all participants completed the first cycle and none experienced a dose limiting toxicity (DLT), the dose was escalated to 20 mg\/kg. If 1 experienced a DLT at 10 mg\/kg, 3 additional participants were assigned to 10 mg\/kg. If no additional participants experienced a DLT, the dose was escalated to 20 mg\/kg. Lenalidomide 25 mg was administered orally once daily for the first 3 weeks of each 4-week cycle. On weeks without elotuzumab, dexamethasone was administered as a single oral (PO) dose of 40 mg. On weeks of elotuzumab infusion, the weekly dose of dexamethasone was administered as a split dose of: 28 mg PO (3 to 24 hours prior to the start of elotuzumab) and 8 mg IV (45 min prior to start of elotuzumab).\n\n$$$\n\n","completion":" Elotuzumab | Dexamethasone | Lenalidomide ###"}
{"prompt":"Title: Elotuzumab 10 mg\/kg Description: Elotuzumab was administered IV at a dose of 10 mg\/kg weekly (Days 1, 8, 15 and 22 of 4-week cycle) for the first 2 cycles and bi-weekly (every 2 weeks) (Day 1 and Day 15) thereafter until disease progression or unacceptable toxicity became apparent. Lenalidomide 25 mg was administered PO once daily for the first 3 weeks of each 4-week cycle. The dose of lenalidomide was administered at least 2-4 hours after completion of elotuzumab infusion. On weeks without elotuzumab administration, dexamethasone was administered PO as a single dose of 40 mg. On weeks of elotuzumab infusion, the weekly dose of dexamethasone was administered as a split dose of: 28 mg PO (between 3 to 24 hours prior to the start of the elotuzumab infusion) and 8 mg IV (At least 45 min prior to the start of the elotuzumab infusion).\n\n$$$\n\n","completion":" Lenalidomide | Elotuzumab | Dexamethasone ###"}
{"prompt":"Title: Elotuzumab 10 mg\/kg Description: Elotuzumab was intravenously (IV) injected at a dose of 10 mg\/kg weekly (Days 1, 8, 15 and 22 of 4-week cycle) for the first 2 cycles and bi-weekly (every 2 weeks) (Day 1 and Day 15) thereafter until disease progression or unacceptable toxicity became apparent. Lenalidomide 25 mg was administered orally once daily for the first 3 weeks of each 4-week cycle. The dose of lenalidomide was administered at least 2-4 hours after completion of elotuzumab infusion. On weeks without elotuzumab administration, dexamethasone was administered as a single dose of 40 mg PO. On weeks of elotuzumab infusion, the weekly dose of dexamethasone was administered as a split dose of: 28 mg PO (between 3 to 24 hours prior to the start of the elotuzumab infusion) AND 8 mg IV (At least 45 min prior to the start of the elotuzumab infusion).\n\n$$$\n\n","completion":" Lenalidomide | Elotuzumab | Dexamethasone ###"}
{"prompt":"Title: Elotuzumab 20 mg\/kg Description: Elotuzumab 20 mg\/kg was intravenously (IV) given weekly (Days 1, 8, 15 and 22 of 4-week cycle) for the first 2 cycles and bi-weekly (every 2 weeks) (Day 1 and Day 15) thereafter until disease progression or unacceptable toxicity. Elotuzumab was first given at 10 mg\/kg. If all participants completed the first cycle and none experienced a dose limiting toxicity (DLT), the dose was escalated to 20 mg\/kg. If 1 experienced a DLT at 10 mg\/kg, 3 additional participants were assigned to 10 mg\/kg. If no additional participants experienced a DLT, the dose was escalated to 20 mg\/kg. Lenalidomide 25 mg was administered orally once daily for the first 3 weeks of each 4-week cycle. On weeks without elotuzumab, dexamethasone was administered as a single oral (PO) dose of 40 mg. On weeks of elotuzumab infusion, the weekly dose of dexamethasone was administered as a split dose of: 28 mg PO (3 to 24 hours prior to the start of elotuzumab) and 8 mg IV (45 min prior to start of elotuzumab).\n\n$$$\n\n","completion":" Lenalidomide | Dexamethasone | Elotuzumab ###"}
{"prompt":"Title: Elotuzumab 20 mg\/kg Description: Elotuzumab was administered IV at a dose of 20 mg\/kg weekly (Days 1, 8, 15 and 22 of 4-week cycle) for the first 2 cycles and bi-weekly (every 2 weeks) (Day 1 and Day 15) thereafter until disease progression or unacceptable toxicity became apparent. Lenalidomide 25 mg was administered PO once daily for the first 3 weeks of each 4-week cycle. The dose of lenalidomide was administered at least 2-4 hours after completion of elotuzumab infusion. On weeks without elotuzumab administration, dexamethasone was administered PO as a single dose of 40 mg. On weeks of elotuzumab infusion, the weekly dose of dexamethasone was administered as a split dose of: 28 mg PO (between 3 to 24 hours prior to the start of the elotuzumab infusion) and 8 mg IV (At least 45 min prior to the start of the elotuzumab infusion).\n\n$$$\n\n","completion":" Lenalidomide | Dexamethasone | Elotuzumab ###"}
{"prompt":"Title: Elotuzumab 20 mg\/kg Description: Elotuzumab was intravenously (IV) injected at a dose of 20 mg\/kg weekly (Days 1, 8, 15 and 22 of 4-week cycle) for the first 2 cycles and bi-weekly (every 2 weeks) (Day 1 and Day 15) thereafter until disease progression or unacceptable toxicity became apparent. Lenalidomide 25 mg was administered orally once daily for the first 3 weeks of each 4-week cycle. The dose of lenalidomide was administered at least 2-4 hours after completion of elotuzumab infusion. On weeks without elotuzumab administration, dexamethasone was administered as a single dose of 40 mg PO. On weeks of elotuzumab infusion, the weekly dose of dexamethasone was administered as a split dose of: 28 mg PO (between 3 to 24 hours prior to the start of the elotuzumab infusion) AND 8 mg IV (At least 45 min prior to the start of the elotuzumab infusion).\n\n$$$\n\n","completion":" Lenalidomide | Dexamethasone | Elotuzumab ###"}
{"prompt":"Title: Erlotinib and Bevacizumab Description: Patients received erlotinib 150 mg daily with bevacizumab at 15mg\/kg until progression or prohibitive toxicity.\n\n$$$\n\n","completion":" Erlotinib | Bevacizumab ###"}
{"prompt":"Title: Escitalopram Plus Acamprosate Description: Escitalopram 10-30mg\/day plus acamprosate 333mg, 2 tabs tid\n\n$$$\n\n","completion":" Escitalopram | Acamprosate ###"}
{"prompt":"Title: Escitalopram Plus Placebo Description: Escitalopram 10-30mg\/day plus placebo 2 tabs tid that resembles acamprosate\n\n$$$\n\n","completion":" Placebo | Escitalopram ###"}
{"prompt":"Title: Ezetimibe\/Simvastatin Description: Ezetimibe\/simvastatin 10\/20 mg tablets, taken once daily for six weeks\n\n$$$\n\n","completion":" Ezetimibe | Simvastatin ###"}
{"prompt":"Title: Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion Description: Fludarabine 30 mg\/m^2 IV daily over 30 minutes for 4 Days (Beginning Day -4).\n\nLower-Dose Melphalan 100 mg\/m^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg\/m^2 IV infused starting on day -5.\n\n$$$\n\n","completion":" Melphalan | Fludarabine ###"}
{"prompt":"Title: Fludarabine + Melphalan + Stem Cell Infusion Description: Fludarabine 30 mg\/m^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).\n\nMelphalan 140 mg\/m^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg\/m^2 IV infused starting on day -5.\n\n$$$\n\n","completion":" Melphalan | Fludarabine ###"}
{"prompt":"Title: Fludarabine + Melphalan + Umbilical Cord Blood Unit Description: Fludarabine 30 mg\/m^2 given daily for four days. Melphalan 140 mg\/m^2 given for one day. Umbilical Cord Blood Unit given on one day.\n\n$$$\n\n","completion":" Fludarabine | Melphalan ###"}
{"prompt":"Title: G-CSF Plus Plerixafor Description: Patients who were unable to mobilize a minimum number of cells (CD34+ cell count <20 cells\/ul)following 5 days of G-CSF mobilization.\n\n$$$\n\n","completion":" G-CSF  | Plerixafor ###"}
{"prompt":"Title: High CIWAar Flumazenil\/Gabapentin Description: 2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.\n\n$$$\n\n","completion":" Flumazenil | Gabapentin ###"}
{"prompt":"Title: High Dose Edoxaban\/Placebo Warfarin Description: Edoxaban tablets plus warfarin placebo tablets\n\n60mg Edoxaban tablets (high dose regimen): Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months\n\nplacebo warfarin: placebo warfarin\n\n$$$\n\n","completion":" Edoxaban | Placebo ###"}
{"prompt":"Title: Ibrutinib+ Bortezomib+ Dexamethasone Description: Ibrutinib (I): I 840 mg orally, once daily continuously starting day 1 of Cycle (C) 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation Bortezomib (B): C 1-8: (21-day C): B 1.3 mg\/m^2 sub-cutaneously on days 1, 4, 8, and 11 of each C C 9-12: (42-day C): B 1.3 mg\/m^2 sub-cutaneously on days 1, 8, 22 and 29 of each C Dexamethasone (D): C 1-8: (21-day C): D 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each C C 9-12: (42-day C): D 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each C C 13+ (28-day C): D 40 mg orally once weekly Dose adjustment of D to 10 mg on days specified during C 1-12 and 20 mg weekly during C 13+ is recommended for subjects >75 years of age.\n\nFollowing implementation of Protocol Amendment 4, D administration was reduced to Days 1, 4, 8 and 11 during each 21-day C (C 1-8) and on Days 1, 8, 22 and 29 on each 42-day C (C 9-12) and unchanged thereafter.\n\n$$$\n\n","completion":" Bortezomib | Dexamethasone | Ibrutinib ###"}
{"prompt":"Title: Ibrutinib+ Bortezomib+ Dexamethasone Description: Ibrutinib (I): I 840 mg orally, once daily continuously starting day 1 of Cycle (C) 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation Bortezomib (B): C 1-8: (21-day C): B 1.3 mg\/m^2 sub-cutaneously on days 1, 4, 8, and 11 of each C C 9-12: (42-day C): B 1.3 mg\/m^2 sub-cutaneously on days 1, 8, 22 and 29 of each C Dexamethasone (D): C 1-8: (21-day C): D 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each C C 9-12: (42-day C): D 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each C C 13+ (28-day C): D 40 mg orally once weekly Dose adjustment of D to 10 mg on days specified during C 1-12 and 20 mg weekly during C 13+ is recommended for subjects >75 years of age.\n\nFollowing implementation of Protocol Amendment 4, D administration was reduced to Days 1, 4, 8, and 11 during each 21-day C (C 1-8) and on Days 1, 8, 22 and 29 on each 42-day C (C 9-12) and unchanged thereafter\n\n$$$\n\n","completion":" Bortezomib | Ibrutinib | Dexamethasone ###"}
{"prompt":"Title: Immediate Switch Description: Patients randomized to the immediate switch group continued treatment with donepezil through the evening prior to Day 8 of the study. On Day 8, all patients began open-label treatment with 5 cm^2 rivastigmine patch formulation. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.\n\n$$$\n\n","completion":" Donepezil | Rivastigmine ###"}
{"prompt":"Title: Insulin Lispro + rHuPH20 Description: Two, subcutaneous (SC) injections of 0.15 units per kilogram (U\/kg) insulin lispro with 3.75 nanograms per kilogram (ng\/kg) recombinant human hyaluronidase (rHuPH20), 9 to 42 days apart\n\n$$$\n\n","completion":" Insulin Lispro | Rhuph20 ###"}
{"prompt":"Title: Lenalidomide + Dexamethasone Description: Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug\n\nDexamethasone: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug\n\n$$$\n\n","completion":" Lenalidomide | Dexamethasone ###"}
{"prompt":"Title: Low CIWA Flumazenil\/Gabapentin Description: 2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.\n\n$$$\n\n","completion":" Flumazenil | Gabapentin ###"}
{"prompt":"Title: Low Dose Edoxaban\/Placebo Warfarin Description: Edoxaban tablets plus warfarin placebo tablets\n\n30mg Edoxaban tablets (low dose regimen): Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months\n\nplacebo warfarin: placebo warfarin\n\n$$$\n\n","completion":" Placebo | Edoxaban ###"}
{"prompt":"Title: Multiple Myeloma (MM) Patients Description: New diagnosis, high risk smoldering MM, relapse as defined by investigator. Participants received 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET\/MRI, Sodium Acetate (C-11 acetate) PET\/CT, C-11 PET\/MRI, and F-18 FDG PET\/CT. Each participant received both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.\n\nFludeoxyglucose: Route of administration was intravenous. Dose of each injection was the standard 5 to 10 millicurie (mCi).\n\nSodium Acetate C11: Route of administration was intravenous. Dose of each injection was 10 mCi (370 MBq).\n\n$$$\n\n","completion":" Sodium Acetate  | Fludeoxyglucose ###"}
{"prompt":"Title: NTx\u00ae-265 High Dose Description: hCG 385 \u00b5g (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation\n\n$$$\n\n","completion":" Epo | Hcg ###"}
{"prompt":"Title: NTx\u00ae-265 Low Dose Description: hCG 385 \u00b5g (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation\n\n$$$\n\n","completion":" Epo | Hcg ###"}
{"prompt":"Title: NTx\u00ae-265 Medium Dose Description: hCG 385 \u00b5g (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation\n\n$$$\n\n","completion":" Hcg | Epo ###"}
{"prompt":"Title: Naltrexone Plus Gabapentin and CBI Description: Naltrexone plus gabapentin and CBI individual counseling for 6 weeks then naltrexone and CBI for 10 additional weeks.\n\n$$$\n\n","completion":" Naltrexone | Gabapentin ###"}
{"prompt":"Title: Naltrexone Plus Placebo and CBI Description: Naltrexone plus placebo and CBI individual counseling for 6 weeks then naltrexone and CBI counseling for 10 weeks.\n\n$$$\n\n","completion":" Naltrexone | Placebo ###"}
{"prompt":"Title: Non-Hodgkin's: ABT-888 & Cyclophosphamide Description: Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.\n\n$$$\n\n","completion":" Abt-888 | Cyclophosphamide ###"}
{"prompt":"Title: OAT + BMM + Beta-B Description: Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)\n\n$$$\n\n","completion":" Propranolol | Nadolol ###"}
{"prompt":"Title: OAT + Beta Blocker (Beta-B) Description: Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)\n\n$$$\n\n","completion":" Nadolol | Propranolol ###"}
{"prompt":"Title: Oral Risperidone Aka Risperal Description: Oral Risperidone aka Risperdal. Participants who were randomized to take oral risperidone were titrated over two weeks up to a target dose of 4 mg per day. The maximum daily dose of oral risperidone was 6 mg.\n\n$$$\n\n","completion":" Risperal | Risperidone ###"}
{"prompt":"Title: Paclitaxel, Ifosfamide, and Cisplatin Description: -Paclitaxel is administered first, 120 mg\/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg\/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg\/m2 daily for five days every three weeks for four cycles.\n\npegfilgrastim\n\ncisplatin\n\nifosfamide\n\npaclitaxel\n\n$$$\n\n","completion":" Paclitaxel | Ifosfamide | Cisplatin ###"}
{"prompt":"Title: Part 2: VMP (Velcade+Melphalan+Prednisone) Description: Velcade 1.3 mg\/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg\/m2 and prednisone 60 mg\/m2 were taken orally.\n\n$$$\n\n","completion":" Melphalan | Velcade | Prednisone ###"}
{"prompt":"Title: Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab Description: Siltuximab 11 mg\/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. VMP: Velcade 1.3 mg\/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg\/m2 and prednisone 60 mg\/m2 were taken orally.\n\n$$$\n\n","completion":" Melphalan | Siltuximab | Velcade | Prednisone ###"}
{"prompt":"Title: Pembrolizumab + Epacadostat Description: Participants received pembrolizumab 200 mg as an intravenous (IV) infusion, every three weeks (Q3W) starting on Day 1 of each cycle for up to 35 administrations in combination with epacadostat 100 mg orally, twice daily. Epacodostat administration was discontinued after the implementation of protocol amendment 05.\n\n$$$\n\n","completion":" Epacadostat | Pembrolizumab ###"}
{"prompt":"Title: Pembrolizumab + Placebo Description: Participants received pembrolizumab 200 mg by IV infusion, Q3W starting on Day 1 of each cycle for up to 35 administrations in combination with matching placebo orally, twice daily. Placebo administration was discontinued after the implementation of protocol amendment 05.\n\n$$$\n\n","completion":" Pembrolizumab | Placebo ###"}
{"prompt":"Title: Phase 1: Dose Finding (560mg) Description: Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO\n\nIbrutinib (560mg)\n\nPomalidomide (4mg)\n\nDexamethasone (40mg)\n\n$$$\n\n","completion":" Pomalidomide | Dexamethasone | Ibrutinib ###"}
{"prompt":"Title: Phase 1: Dose Finding (840mg) Description: Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO\n\nIbrutinib (840mg)\n\nPomalidomide (4mg)\n\nDexamethasone (40mg)\n\n$$$\n\n","completion":" Ibrutinib | Pomalidomide | Dexamethasone ###"}
{"prompt":"Title: Phase I Dose Finding Description: Decitabine at escalating dose levels will be given IV for 1 hour x 5 days followed by Carboplatin given IV for 30 minutes on Day 8 at a dose corresponding to an AUC of 5.\n\n$$$\n\n","completion":" Decitabine | Carboplatin ###"}
{"prompt":"Title: Phase I Dose Finding Description: Standard treatment of sirolimus and tacrolimus as GvHD prophylaxis with sirolimus (target plasma drug level of 5-10 ng\/ml) and lenalidomide (15 mg daily) as post-transplant maintenance\n\n$$$\n\n","completion":" Lenalidomide | Sirolimus | Tacrolimus ###"}
{"prompt":"Title: Placebo Description: Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS\/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol\/salbutamol inhalation aerosol to be used as needed throughout the study.\n\n$$$\n\n","completion":" Albuterol | Salbutamol ###"}
{"prompt":"Title: Placebo + Carboplatin + Paclitaxel -> Placebo Description: Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve [AUC] of 6 mg per milliliter per minute (mg\/mL\/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg\/m\u00b2) of body-surface area (BSA), administered every 3 weeks, or 80 mg\/m\u00b2 administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.\n\n$$$\n\n","completion":" Paclitaxel | Carboplatin | Placebo ###"}
{"prompt":"Title: Placebo First, Then Varenicline Description: Placebo for one week; followed by Varenicline, oral target dose of 1.0 mg BID, one week titration.\n\n$$$\n\n","completion":" Varenicline | Placebo ###"}
{"prompt":"Title: Placebo q2w Description: 2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20.\n\n$$$\n\n","completion":" Placebo | Prednisolone | Prednisone ###"}
{"prompt":"Title: Placebo q2w Description: 2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until week 20.\n\n$$$\n\n","completion":" Prednisolone | Placebo | Prednisone ###"}
{"prompt":"Title: Placebo+tDCS+Speech Therapy Description: 1.5 mA anodal tDCS, and speech therapy for 1 day\n\nActive tDCS: 1.5 mA tDCS anodal tDCS\n\nSpeech Therapy: 60 min of speech therapy\n\nPlacebo\n\n$$$\n\n","completion":" Placebo | Tdcs ###"}
{"prompt":"Title: Placebo+tDCS+Speech Therapy Description: The subjects received placebo 30 minutes before the 60 minutes of SLT; first 20 min is simultaneous tDCS stimulation in this experiment\/arm.\n\n$$$\n\n","completion":" Tdcs | Placebo ###"}
{"prompt":"Title: Randomized: Daratumumab+RVd (D-RVd) Description: Induction and Consolidation Phase (12 week induction phase followed by autologous stem cell mobilization, HDT and ASCT; a 6-week consolidation phase)-participants received RVd with daratumumab 16 milligram per kilogram (mg\/kg) intravenously (IV) weekly on Days 1, 8, and 15 of Cycles 1 to 4 during induction treatment and every 3 weeks on Day 1 of Cycles 5 and 6 during consolidation treatment; Maintenance phase (up to 104-week [until disease progression\/up to maximum of 2 years])- participants received daratumumab 16 mg every 4 weeks\/8 weeks plus lenalidomide 10 mg orally on Days 1 to 21 throughout each 28-day cycle on Cycles 7 through 9 during maintenance treatment. Beginning at Cycle 10, the lenalidomide dose was increased to 15 mg, unless there was a tolerability concern. Long-term follow-up phase- all participants are followed for at least 1 year after last dose of study drug and to continue until death, withdrawal of consent or end of study.\n\n$$$\n\n","completion":" Daratumumab | Lenalidomide ###"}
{"prompt":"Title: Randomized: Lenalidomide+Bortezomib+Dexamethasone (RVd) Description: Induction and Consolidation Phase (12-week induction phase followed by autologous stem cell mobilization, high-dose chemotherapy [HDT] and autologous stem cell transplantation [ASCT]; 6-week consolidation phase)- participants received lenalidomide 25 milligram (mg) orally on Days 1 to 14 of Cycles 1 through 6), bortezomib 1.3 milligram per meter square (mg\/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11 and dexamethasone 40 mg orally weekly (20 mg on Days 1, 2, 8, 9, 15 and 16); Maintenance phase (up to 104 week [until disease progression\/up to maximum of 2 years])- participants received lenalidomide 10 mg orally on Days 1 to 21 throughout each 28-day cycle on Cycles 7 through 9 during maintenance treatment. Beginning at Cycle 10, lenalidomide dose was increased to 15 mg, unless there was tolerability concern. Long-term follow-up phase- all participants are followed for at least 1 year after last dose of study drug and to continue until death, withdrawal of consent or end of study.\n\n$$$\n\n","completion":" Dexamethasone | Bortezomib | Lenalidomide ###"}
{"prompt":"Title: Regular Human Insulin + rHuPH20 Description: Two, subcutaneous (SC) injections of 0.15 units per kilogram (U\/kg) regular human insulin (RHI) with 3.75 nanograms per kilogram (ng\/kg) recombinant human hyaluronidase (rHuPH20), 9 to 42 days apart\n\n$$$\n\n","completion":" Rhuph20 | Insulin ###"}
{"prompt":"Title: SRT501 + Bortezomib Description: The eligible participants in this arm received an intravenous solution of Bortezomib at 1.3 mg\/m^2 in conjunction with SRT501 (5.0 g\/day) daily dosing. Bortezomib was administered prior to breakfast and SRT501 administration, on Day 1, 4, 8 and 11 in every 21 day cycle. It was given as per the local institution's guidelines and standards of care. SRT501 + Bortezomib, is a subset of arm SRT501 monotherapy.\n\n$$$\n\n","completion":" Bortezomib | Srt501 ###"}
{"prompt":"Title: SRT501 + Bortezomib Description: The eligible participants in this arm received an intravenous solution of Bortezomib at 1.3 mg\/m^2 in conjunction with SRT501 (5.0 g\/day) daily dosing. Bortezomib was administered prior to breakfast and SRT501 administration, on Day 1, 4, 8 and 11 in every 21 day cycle. It was given as per the local institution's guidelines and standards of care.SRT501 + Bortezomib, is a subset of arm SRT501 monotherapy.\n\n$$$\n\n","completion":" Srt501 | Bortezomib ###"}
{"prompt":"Title: Salmeterol 50 \u00b5g BID Description: Participants received Salmeterol 50 \u00b5g BID from the DISKUS\/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol\/salbutamol aerosol to be used as needed throughout the study.\n\n$$$\n\n","completion":" Salbutamol | Salmeterol | Albuterol ###"}
{"prompt":"Title: Standard of Care Narcotic Therapy Description: Morphine intravenous (IV), 4 mg TID for 24 hours, followed by oxycodone hydrochloride tablet, 10 mg TID for 6 days.\n\nMorphine: Morphine\n\nOxycodone Hydrochloride: Oxycodone Hydrochloride 10 mg tablet\n\n$$$\n\n","completion":" Oxycodone | Morphine ###"}
{"prompt":"Title: Treatment A Description: Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions\n\n$$$\n\n","completion":" Saxagliptin | Glucophage ###"}
{"prompt":"Title: Treatment B Description: Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions\n\n$$$\n\n","completion":" Metformin | Saxagliptin ###"}
{"prompt":"Title: Triple-negative Breast Cancer: Crossover Description: Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.\n\n$$$\n\n","completion":" Cyclophosphamide | Abt-888 ###"}
{"prompt":"Title: Triple-negative Breast Cancer: Cyclophosphamide & ABT-888 Description: Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth on a continuous schedule.\n\n$$$\n\n","completion":" Cyclophosphamide | Abt-888 ###"}
{"prompt":"Title: Varenicline First, Then Placebo Description: Varenicline, oral target dose of 1.0 mg BID, one week titration; followed by placebo, matched for one week.\n\n$$$\n\n","completion":" Placebo | Varenicline ###"}
{"prompt":"Title: Varenicline First, Then Placebo Description: Varenicline, oral target dose of 1.0 mg BID, one week titration; placebo, matched for one week.\n\n$$$\n\n","completion":" Placebo | Varenicline ###"}
{"prompt":"Title: Veliparib + Carboplatin + Paclitaxel -> Placebo Description: Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg\/mL\/min every 3 weeks and paclitaxel 175 mg\/m\u00b2 of BSA administered every 3 weeks, or 80 mg\/m\u00b2 administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.\n\n$$$\n\n","completion":" Veliparib | Paclitaxel | Carboplatin ###"}
{"prompt":"Title: Veliparib + Carboplatin + Paclitaxel -> Veliparib Description: Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg\/mL\/min every 3 weeks and paclitaxel 175 mg\/m\u00b2 of BSA administered every 3 weeks, or 80 mg\/m\u00b2 administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.\n\n$$$\n\n","completion":" Veliparib | Paclitaxel | Carboplatin ###"}
{"prompt":"Title: Vilanteral 25 \u00b5g OD Description: Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS\/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol\/salbutamol aerosol to be used as needed throughout the study.\n\n$$$\n\n","completion":" Salbutamol | Albuterol | Vilanterol ###"}
{"prompt":"Title: Warfarin\/Placebo Edoxaban Description: Warfarin tablets plus placebo Edoxaban tablets\n\nwarfarin tablets: Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months\n\nplacebo edoxaban: placebo edoxaban\n\n$$$\n\n","completion":" Warfarin | Placebo ###"}
{"prompt":"Title: 0.1 g\/kg Octagam 10% Every 2 Weeks Description: Participants received 0.1 g\/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).\n\n$$$\n\n","completion":" Octagam ###"}
{"prompt":"Title: 0.2 g\/kg Octagam 10% Every 4 Weeks Description: Participants received 0.2 g\/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).\n\n$$$\n\n","completion":" Octagam ###"}
{"prompt":"Title: 0.25 g\/kg Octagam 10% Every 2 Weeks Description: Participants received 0.25 g\/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).\n\n$$$\n\n","completion":" Octagam ###"}
{"prompt":"Title: 0.4 g\/kg Octagam 10% Every 2 Weeks Description: Participants received of 0.4 g\/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).\n\n$$$\n\n","completion":" Octagam ###"}
{"prompt":"Title: 0.5 g\/kg Octagam 10% Every 4 Weeks Description: Participants received 0.5 g\/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).\n\n$$$\n\n","completion":" Octagam ###"}
{"prompt":"Title: 0.8 g\/kg Octagam 10% Every 4 Weeks Description: Participants received of 0.8 g\/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).\n\n$$$\n\n","completion":" Octagam ###"}
{"prompt":"Title: 1% OPC-12759 Ophthalmic Suspension Description: 1% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.\n\n$$$\n\n","completion":" Opc-12759 ###"}
{"prompt":"Title: 1. Pioglitazone Description: Pioglitazone: Pioglitazone tablets; 30 mg\/day for 2 weeks; then increased to 45 mg\/day until week 12 (approximately 3 months)\n\n$$$\n\n","completion":" Pioglitazone ###"}
{"prompt":"Title: 2% OPC-12759 Ophthalmic Suspension Description: 2% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.\n\n$$$\n\n","completion":" Opc-12759 ###"}
{"prompt":"Title: 2. Placebo Description: Placebo: Matching placebo (inert tablet)\n\n$$$\n\n","completion":" Placebo ###"}
{"prompt":"Title: Acamprosate Description: Acamprosate tablets\n\n$$$\n\n","completion":" Acamprosate ###"}
{"prompt":"Title: Active Description: Intranasal oxytocin doses 2-3 times\/day for 12 weeks\n\nIntranasal Oxytocin: 10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks\n\n$$$\n\n","completion":" Oxytocin ###"}
{"prompt":"Title: Albiglutide Description: Albiglutide was administered once weekly as subcutaneous injection in the abdomen, thigh or upper arm region. Participants were administered albiglutide at a dose of 30 milligrams (mg) or 50 mg once weekly in addition to the standard of care therapy for diabetes and cardiovascular health.\n\n$$$\n\n","completion":" Albiglutide ###"}
{"prompt":"Title: Aliskiren\/HCTZ Description: Aliskiren \/ HCTZ 150\/12.5 mg for 1 week followed by 300\/25 mg for 7 weeks\n\n$$$\n\n","completion":" Aliskiren \/ HCTZ ###"}
{"prompt":"Title: Alkeran Description: Open-label, randomized, cross-over design study where Propylene Glycol Free Melphalan and Alkeran were assessed in the same multiple myeloma patients. This group includes all patients with Alkeran dose administration regardless of cross over sequence\n\n$$$\n\n","completion":" Alkeran ###"}
{"prompt":"Title: Aminophylline 250 mg Description: Aminophylline 250 mg IV drip administration\n\n$$$\n\n","completion":" Aminophylline ###"}
{"prompt":"Title: Amlodipine Description: Amlodipine 5 mg for 1 week followed by 10 mg for 7 weeks\n\n$$$\n\n","completion":" Amlodipine ###"}
{"prompt":"Title: Aprepitant: 125mg\/Day Description: 125mg\/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.\n\n$$$\n\n","completion":" Aprepitant ###"}
{"prompt":"Title: Aripiprazole Description: aripiprazole daily for 3 months\n\n$$$\n\n","completion":" Aripiprazole ###"}
{"prompt":"Title: Arm 1 Description: sodium valproate\n\nValproate: 250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60mg per day. Usual dosage is between 1250mg to 2000mg per day\n\n$$$\n\n","completion":" sodium valproate  ###"}
{"prompt":"Title: Arm 1: Pioglitazone Description: Current or former smokers receive 6 months of treatment with pioglitazone\n\nfluorescence bronchoscopy: examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.\n\nquantitative high resolution CT scan: High resolution CT scan of the chest\n\nPIOGLITAZONE VS. PLACEBO 30 mg: Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-\n\nactivated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials.\n\n$$$\n\n","completion":" Pioglitazone ###"}
{"prompt":"Title: Arm 2 Description: naltrexone\n\nNaltrexone: 25mg per day, taken by mouth for 7 days, then 50mg per day\n\n$$$\n\n","completion":" Naltrexone ###"}
{"prompt":"Title: Arm 2: Placebo Description: Current or former smokers receive 6 months of treatment with placebo\n\nfluorescence bronchoscopy: examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.\n\nquantitative high resolution CT scan: High resolution CT scan of the chest\n\n$$$\n\n","completion":" Placebo ###"}
{"prompt":"Title: BRCA-positive Ovarian Cancer: Cyclophosphamide Alone Description: Oral cyclophosphamide 50mg by mouth (PO) for 21 days.\n\n$$$\n\n","completion":" Cyclophosphamide ###"}
{"prompt":"Title: Baclofen Description: Baclofen capsules: 15 mg\/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg\/day (10 mg t.i.d.; target dose) until the alcohol laboratory session; then, 15 mg\/day (5 mg t.i.d.; taper down) for three additional days.\n\n$$$\n\n","completion":" Baclofen ###"}
{"prompt":"Title: Benra 30mg Description: Benralizumab administered subcutaneously every 4 weeks\n\n$$$\n\n","completion":" Benralizumab ###"}
{"prompt":"Title: Benralizumab 100 mg Description: Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.\n\n$$$\n\n","completion":" Benralizumab ###"}
{"prompt":"Title: Benralizumab 200 mg Description: Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.\n\n$$$\n\n","completion":" Benralizumab ###"}
{"prompt":"Title: Benralizumab 25 mg Description: Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.\n\n$$$\n\n","completion":" Benralizumab ###"}
{"prompt":"Title: Botulinum Toxin 200 Units Description: 200 units of Botox\u00ae\n\n$$$\n\n","completion":" Botulinum Toxins ###"}
{"prompt":"Title: Botulinum Toxin 300 Units Description: 300 units of Botox\u00ae\n\n$$$\n\n","completion":" Botulinum Toxins ###"}
{"prompt":"Title: Budesonide Description: Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily.\n\n$$$\n\n","completion":" Budesonide ###"}
{"prompt":"Title: Buprenorphine Sublingual Spray 0.5 mg Description: Buprenorphine Sublingual Spray 0.5 milligrams (mg) three times a day (TID) for 7 days.\n\nBuprenorphine Sublingual Spray: Buprenorphine Sublingual Spray 0.5 mg\n\n$$$\n\n","completion":" Buprenorphine ###"}
{"prompt":"Title: Bupropion Description: Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days.\n\nBupropion: Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.\n\n$$$\n\n","completion":" Bupropion ###"}
{"prompt":"Title: CMV Reactivation Patients With GCV Description: CMV reactivation patients with intravenous Ganciclovir followed by oral Ganciclovir.\n\n$$$\n\n","completion":" Ganciclovir ###"}
{"prompt":"Title: Celecoxib Description: Participants\n\n$$$\n\n","completion":" Celecoxib ###"}
{"prompt":"Title: Celecoxib Description: Patients receiving celebrex preoperative and postoperatively for 7 days\n\nCelecoxib\n\n$$$\n\n","completion":" Celecoxib ###"}
{"prompt":"Title: Citicoline Description: Citicoline will be started at 500 mg\/day at the randomization visit (week 0), then increased to 1000 mg\/day at week 2, then 1500 mg\/day at week 4, and then 2000 mg\/day at week 6 until the end of week 12.\n\n$$$\n\n","completion":" Citicoline ###"}
{"prompt":"Title: Clobazam High Dose Description: 1.0 mg\/kg\/day; tablets; orally; for 15-18 weeks\n\n$$$\n\n","completion":" Clobazam ###"}
{"prompt":"Title: Clobazam High Dose Description: 5 to 40 mg\/day with doses in the morning and at bedtime; orally\n\n$$$\n\n","completion":" Clobazam ###"}
{"prompt":"Title: Clobazam Low Dose Description: 0.25 mg\/kg\/day; tablets; orally; for 15-18 weeks\n\n$$$\n\n","completion":" Clobazam ###"}
{"prompt":"Title: Clobazam Low Dose Description: 5 to 10 mg\/day with doses in the morning and at bedtime; orally\n\n$$$\n\n","completion":" Clobazam ###"}
{"prompt":"Title: Clobazam Medium Dose Description: 0.5 mg\/kg\/day; tablets; orally; for 15-18 weeks\n\n$$$\n\n","completion":" Clobazam ###"}
{"prompt":"Title: Condensed RT Group Description: Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.\n\ncondensed RT group: BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U\/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.\n\nTraining procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.\n\nDuring each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice.\n\n$$$\n\n","completion":" Bont-a ###"}
{"prompt":"Title: Control Description: Intranasal placebo doses 2-3 times\/day for 12 weeks\n\nPlacebo: 10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks\n\n$$$\n\n","completion":" Placebo ###"}
{"prompt":"Title: Deep NMB Using Rocuronium Description: The abdomen is insufflated to 13 mmHg pneumoperitoneum with deep NMB (post tetanic count 1-2) during operation\n\nDeep NMB using rocuronium: - Drug: rocuronium\n\nBolus dose: 0.7 mg\/kg\nContinuous infusion : 0.8-1.2 mg\/kg\/h for maintaining deep NMB (post tetanic count 1-2) during operation.\n\n$$$\n\n","completion":" Rocuronium ###"}
{"prompt":"Title: Distributed RT Group Description: Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.\n\ndistributed RT group: BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U\/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.\n\nTraining procedures There are total 24 training sessions following one week after injection. Participants in the distributed practice group will receive 2 sessions per week, for 12 weeks.\n\nDuring each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice.\n\n$$$\n\n","completion":" Bont-a ###"}
{"prompt":"Title: Dutasteride Description: 4 mg oral loading dose of dutasteride followed by 1 mg\/day dutasteride for 12 weeks.\n\nDutasteride\n\n$$$\n\n","completion":" Dutasteride ###"}
{"prompt":"Title: Epidiolex Description: The participants (or their caregivers) self-administered CBD 100mg\/mL oral solution at a starting dose of 5 mg\/kg\/day in twice daily dosing and titrated by 5 mg\/kg\/2 weeks up to 25 mg\/kg\/day. Additional increases in dosing, by 5 mg\/kg\/day up to a maximum of 50 mg\/kg\/day, was instituted at the discretion of the treating PI.\n\n$$$\n\n","completion":" Cbd ###"}
{"prompt":"Title: Extended Release Lamotrigine Description: Once daily dose of extended release lamotrigine given for two weeks following completion of part I of the study (regular lamotrigine)\n\n$$$\n\n","completion":" Lamotrigine ###"}
{"prompt":"Title: GWP42003-P 25 mg\/kg\/Day Description: Participants were randomized to receive GWP42003-P 25 milligrams per kilogram per day (mg\/kg\/day) (via oral twice daily [morning and evening] administration). Participants completed a 4-week dose escalation period, titrating up to their assigned dose, before continuing on a stable dose of blinded GWP42003-P for 12 weeks.\n\n$$$\n\n","completion":" Gwp42003-p ###"}
{"prompt":"Title: GWP42003-P 50 mg\/kg\/Day Description: Participants were randomized to receive GWP42003-P 50 mg\/kg\/day (via oral twice daily [morning and evening] administration). Participants completed a 4-week dose escalation period, titrating up to their assigned dose, before continuing on a stable dose of blinded GWP42003-P for 12 weeks.\n\n$$$\n\n","completion":" Gwp42003-p ###"}
{"prompt":"Title: Gabapentin 1800mg Daily Description: 1800 mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks\n\nbehavioral counseling: The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.\n\ngabapentin 1800mg: 1800 mg gabapentin daily for 12 weeks\n\n$$$\n\n","completion":" Gabapentin ###"}
{"prompt":"Title: Gabapentin 900mg Daily Description: 900mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.\n\nGabapentin 900mg: 900 mg gabapentin daily for 12 weeks\n\nbehavioral counseling: The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.\n\n$$$\n\n","completion":" Gabapentin ###"}
{"prompt":"Title: Haloperidol (Haldol) Description: Patients will receive 2.5 mg of intravenous (IV) haloperidol following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.\n\nHaloperidol: Patients receive 2.5 mg of IV haloperidol.\n\nNormal Saline: All patients receive a 1-liter bolus of normal saline (NS)\n\nDiphenhydramine: All patients receive 25 mg of intravenous (IV) diphenhydramine.\n\n$$$\n\n","completion":" Haloperidol ###"}
{"prompt":"Title: High CIWAar Placebo Description: 20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.\n\n$$$\n\n","completion":" Placebo ###"}
{"prompt":"Title: High Dose Cannabidiol Oral Solution [40 mg\/kg\/Day] Description: High Dose [40 mg\/kg\/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg\/kg in the morning on Day 1 followed by total dose of 40 mg\/kg\/day (20 mg\/kg in the morning and 20 mg\/kg in the evening) on Days 4 to 10.\n\n$$$\n\n","completion":" Cannabidiol ###"}
{"prompt":"Title: Immediate Release (IR) Lamotrigine Description: Study population was on chronic IR lamotrigine therapy and first period of the study was a continuation of standard treatment with IR lamotrigine.\n\n$$$\n\n","completion":" Lamotrigine ###"}
{"prompt":"Title: Insulin Lispro Alone Description: Two, subcutaneous (SC) injections of 0.15 units per kilogram (U\/kg) insulin lispro alone, 9 to 42 days apart\n\n$$$\n\n","completion":" Insulin Lispro ###"}
{"prompt":"Title: Intranasal Midazolam Description: 0.2 mg\/kg Intranasal Midazolam for a seizure longer than 5 minutes\n\n$$$\n\n","completion":" Midazolam ###"}
{"prompt":"Title: Intranasal Midazolam Description: Median time to seizure cessation from medication administration to seizures stop time.\n\n$$$\n\n","completion":" Midazolam ###"}
{"prompt":"Title: Intranasal Midazolam Description: Patients who required oxygen at discharge from the Emergency Department\n\n$$$\n\n","completion":" Midazolam ###"}
{"prompt":"Title: KPI-121 0.25% Ophthalmic Suspension Description: Participants randomized to KPI-121 0.25% Ophthalmic Suspension\n\n$$$\n\n","completion":" Kpi-121 ###"}
{"prompt":"Title: Ketamine Description: Ketamine: A single dose of intranasal ketamine up to 50 mg\n\n$$$\n\n","completion":" Ketamine ###"}
{"prompt":"Title: Ketamine Description: Single bolus 0.5mg\/kg ketamine IV after induction of anesthesia\n\n$$$\n\n","completion":" Ketamine ###"}
{"prompt":"Title: Ketorolac Description: Participants\n\n$$$\n\n","completion":" Ketorolac ###"}
{"prompt":"Title: Ketorolac Description: Patients receiving scheduled ketorolac postoperatively\n\nKetorolac\n\n$$$\n\n","completion":" Ketorolac ###"}
{"prompt":"Title: Lamotrigine Description: Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg\/day over first six weeks, 200 mg\/day fixed-dose maintenance for second six weeks\n\nLamotrigine: Six week titration from 25 mg\/day to 200 mg\/day, then 200 mg\/day maintenance for additional six weeks\n\n$$$\n\n","completion":" Lamotrigine ###"}
{"prompt":"Title: Letrozole Description: 2.5 mg by mouth (PO) daily\n\n$$$\n\n","completion":" Letrozole ###"}
{"prompt":"Title: Levetiracetam Description: Levetiracetam: Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.\n\n$$$\n\n","completion":" Levetiracetam ###"}
{"prompt":"Title: Low CIWAar Placebo Description: 20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.\n\n$$$\n\n","completion":" Placebo ###"}
{"prompt":"Title: Low Dose Cannabidiol Oral Solution [10 mg\/kg\/Day] Description: Low Dose [10 milligrams\/kilogram\/day (mg\/kg\/day)] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg\/kg in the morning on Day 1 followed by total dose of 10 mg\/kg\/day (5 mg\/kg in the morning and 5 mg\/kg in the evening) on Days 4 to 10.\n\n$$$\n\n","completion":" Cannabidiol ###"}
{"prompt":"Title: Low Dose Ondansetron (0.2 mg Bid) Description: ondansetron: ondansetron 0.2 mg bid, oral preparation, 16 weeks\n\n$$$\n\n","completion":" Ondansetron ###"}
{"prompt":"Title: Lurasidone 160 mg Description: Lurasidone 160 mg (4 tablets) taken orally once a day\n\n$$$\n\n","completion":" Lurasidone ###"}
{"prompt":"Title: Lurasidone 80 mg Description: Lurasidone 80 mg tablets taken orally once a day\n\n$$$\n\n","completion":" Lurasidone ###"}
{"prompt":"Title: Matched Placebo Description: Matched Placebo daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.\n\n$$$\n\n","completion":" Placebo ###"}
{"prompt":"Title: Melphalan Description: Open-label, randomized, cross-over design study where Propylene Glycol Free Melphalan and Alkeran were assessed in the same multiple myeloma patients. This group includes all patients with Melphalan dose administration regardless of cross over sequence\n\n$$$\n\n","completion":" Melphalan ###"}
{"prompt":"Title: Metoclopramide (Reglan) Description: Patients will receive 10 mg of intravenous (IV) metoclopramide following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.\n\nMetoclopramide: Patients receive 10 mg of intravenous (IV) metoclopramide.\n\nNormal Saline: All patients receive a 1-liter bolus of normal saline (NS)\n\nDiphenhydramine: All patients receive 25 mg of intravenous (IV) diphenhydramine.\n\n$$$\n\n","completion":" Metoclopramide ###"}
{"prompt":"Title: Metoclopramide Nasal Spray 10 mg Description: metoclopramide: 30 minutes before meals and at bedtime for 4 weeks\n\n$$$\n\n","completion":" Metoclopramide ###"}
{"prompt":"Title: Metoclopramide Nasal Spray 14 mg Description: metoclopramide: 30 minutes before meals and at bedtime for 4 weeks\n\n$$$\n\n","completion":" Metoclopramide ###"}
{"prompt":"Title: Mid Dose Cannabidiol Oral Solution [20 mg\/kg\/Day] Description: Mid Dose [20 mg\/kg\/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg\/kg in the morning on Day 1 followed by total dose of 20 mg\/kg\/day (10 mg\/kg in the morning and 10 mg\/kg in the evening) on Days 4 to 10.\n\n$$$\n\n","completion":" Cannabidiol ###"}
{"prompt":"Title: Moderate Dose Ondansetron (0.8 mg Bid) Description: Ondansetron: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration\n\n$$$\n\n","completion":" Ondansetron ###"}
{"prompt":"Title: Moderate NMB Using Rocuronium Description: The abdomen is insufflated to 13 mmHg pneumoperitoneum with moderate NMB (train of four 1-2) during operation\n\nModerate NMB using rocuronium: - Drug: rocuronium\n\nBolus dose: none\nContinuous infusion: 0.2-0.6 mg\/kg\/h for maintaining moderate NMB (train of four 1-2) during operation.\n\n$$$\n\n","completion":" Rocuronium ###"}
{"prompt":"Title: Montelukast 14 mg Description: Montelukast 14 mg IV Administration\n\n$$$\n\n","completion":" Montelukast ###"}
{"prompt":"Title: Montelukast 7 mg Description: Montelukast 7 mg IV Administration\n\n$$$\n\n","completion":" Montelukast ###"}
{"prompt":"Title: Nalmefene Hydrochloride 10 mg Description: Nalmefene hydrochloride: As-needed; tablets, orally\n\n$$$\n\n","completion":" Nalmefene ###"}
{"prompt":"Title: Nalmefene Hydrochloride 20 mg Description: Nalmefene hydrochloride: As-needed; tablets, orally\n\n$$$\n\n","completion":" Nalmefene ###"}
{"prompt":"Title: Nasal Nicotine Spray Description: 3 mg of nasal nicotine will be administered postoperatively.\n\n$$$\n\n","completion":" Nicotine ###"}
{"prompt":"Title: Nasal Normal Saline Spray Description: 1 ml of nasal normal saline spray will be administered postoperatively.\n\n$$$\n\n","completion":" Placebo ###"}
{"prompt":"Title: Nicotine Patch Description: Transdermal nicotine patch\n\nTransdermal nicotine patch: 7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)\n\n$$$\n\n","completion":" Nicotine ###"}
{"prompt":"Title: Non-Hodgkin's: Cyclophosphamide Alone Description: Oral cyclophosphamide 50mg by mouth (PO) for 21 days.\n\n$$$\n\n","completion":" Cyclophosphamide ###"}
{"prompt":"Title: OAT + BMM + PL Description: Optimal Acute Therapy plus Behavioral Migraine Management plus placebo\n\n$$$\n\n","completion":" Placebo ###"}
{"prompt":"Title: OAT + Placebo (PL) Description: Optimal Acute Therapy plus Beta Blocker Placebo\n\n$$$\n\n","completion":" Placebo ###"}
{"prompt":"Title: Open Trial Group Description: The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.\n\nOlanzapine: 16-week open trial of olanzapine. The patients were started on a dose of 15 mg\/d by mouth, which could be adjusted to as low as 10 mg\/d or as high as 40 mg\/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.\n\n$$$\n\n","completion":" Olanzapine ###"}
{"prompt":"Title: Open-label Extension Arm Description: All participants started treatment with a daily rivastigmine 2.5 cm^2 patch. The dose was increased to 5, 7.5, and then 10 cm^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period) for a total of 52 weeks. A predetermined \"allowed adjustment\" scheme was followed in participants who required dose adjustment due to low tolerability.\n\n$$$\n\n","completion":" Rivastigmine ###"}
{"prompt":"Title: PTOEND Description: PTOEND: Personally-tailored opioid overdose prevention education and naloxone distribution.\n\nParticipants in this arm will be given a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment.\n\nnaloxone nasal spray kit: Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose.\n\nPersonally-tailored opioid overdose prevention education (information packet): Personally-tailored information packet with three participant-specific reports and general written information about opioid overdose and treatment for opioid use disorder.\n\n$$$\n\n","completion":" Naloxone ###"}
{"prompt":"Title: PTOEND+PI Description: PTOEND+PI: Personally-tailored opioid overdose prevention education and naloxone distribution, plus Peer Intervention.\n\nIn addition to a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment, participants randomized to this arm will also receive the experimental Peer Intervention.\n\nPeer Intervention: The Peer Intervention is a 20-minute telephone call delivered by a Peer Interventionist, who is trained to answer questions about the content of the personally-tailored information packets.\n\nnaloxone nasal spray kit: Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose.\n\nPersonally-tailored opioid overdose prevention education (information packet): Personally-tailored information packet with three participant-specific reports and general written information about opioid overdose and treatment for opioid use disorder.\n\n$$$\n\n","completion":" Naloxone ###"}
{"prompt":"Title: Paired no Reward (Methamphetamine Sessions) Description: All subjects received methamphetamine (20 mg) on two conditioning sessions\n\n$$$\n\n","completion":" Methamphetamine ###"}
{"prompt":"Title: Paired, High Reward (Methamphetamine Sessions) Description: All subjects received methamphetamine (20 mg) on two conditioning sessions\n\n$$$\n\n","completion":" Methamphetamine ###"}
{"prompt":"Title: Paired, Low Reward (Methamphetamine Sessions) Description: All subjects received methamphetamine (20 mg) on two conditioning sessions\n\n$$$\n\n","completion":" Methamphetamine ###"}
{"prompt":"Title: Paliperidone Description: Paliperidone Extended-Release (ER) oral tablet was administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.\n\n$$$\n\n","completion":" Paliperidone ###"}
{"prompt":"Title: Paroxetine Description: Paroxetine\n\nParoxetine: 16 weeks treatment; dosing will start at 20 mg\/day paroxetine and will increase gradually to a maximum dose of 60 mg\/day\n\n$$$\n\n","completion":" Paroxetine ###"}
{"prompt":"Title: Part B: E2006 10 mg Description: Otherwise healthy participants with primary insomnia received E2006 10 mg, capsule, orally in the evening, 30 minutes prior to habitual bed time (lights-out) on Day 1.\n\n$$$\n\n","completion":" E2006 ###"}
{"prompt":"Title: Part B: E2006 2.5 mg Description: Otherwise healthy participants with primary insomnia received E2006 2.5 mg, capsule, orally in the evening, 30 minutes prior to habitual bed time (lights-out) on Day 1.\n\n$$$\n\n","completion":" E2006 ###"}
{"prompt":"Title: Part B: E2006 25 mg Description: Otherwise healthy participants with primary insomnia received E2006 25 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each), orally in the evening, 30 minutes prior to habitual bed time (lights-out) on Day 1.\n\n$$$\n\n","completion":" E2006 ###"}
{"prompt":"Title: Part B: E2006 Matched Placebo or Zolpidem Matched Placebo Description: Otherwise healthy participants with primary insomnia received E2006-matched placebo capsules or zolpidem-matched placebo tablets, orally in the evening, 30 minutes prior to habitual bed time (lights-out) on Day 1.\n\n$$$\n\n","completion":" Placebo ###"}
{"prompt":"Title: Part B: Zolpidem 10 mg Description: Otherwise healthy participants with primary insomnia received zolpidem 10 mg immediate release, tablet, orally in the evening, 30 minutes prior to habitual bed time (lights-out) on Day 1.\n\n$$$\n\n","completion":" Zolpidem ###"}
{"prompt":"Title: Pen (Period 1) \/ Vial & Syringe (Period 2) Description: Crossover study group of insulin glargine via SoloSTAR\u00ae pen in Period 1 and insulin glargine via vial and syringe in Period 2.\n\n$$$\n\n","completion":" Insulin Glargine ###"}
{"prompt":"Title: Pen (Period 1) \/ Vial & Syringe (Period 2) Description: Crossover study group where participants were randomized to the sequence of insulin glargine via SoloSTAR\u00ae pen in Period 1 and insulin glargine via vial and syringe in Period 2.\n\n$$$\n\n","completion":" Insulin Glargine ###"}
{"prompt":"Title: Placebo Description: 0% OPC-12759 ophthalmic suspension received one drop of to both eyes four times a day for 4 weeks\n\n$$$\n\n","completion":" Placebo ###"}
